Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 410521, 5 pages
http://dx.doi.org/10.1155/2013/410521
Clinical Study

Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients

1Unità di Reumatologia, Istituto Dermopatico dell’Immacolata-IRCCS, Via Monti di Creta 104, 00165 Rome, Italy
2Unità di Reumatologia, Ospedale S. Pietro Fatebenefratelli, Via Cassia 600, 00189 Rome, Italy
3Unità di Dermatologia, Istituto Dermopatico dell’Immacolata-IRCCS, Via Monti di Creta 104, 00165 Rome, Italy
4Unità di Gastroenterologia, Ospedale San Carlo, Via Aurelia 275, 00165 Rome, Italy

Received 16 October 2012; Revised 12 February 2013; Accepted 18 February 2013

Academic Editor: Tae-Hwan Kim

Copyright © 2013 R. Laurenti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

R. Laurenti, F. Giovannangeli, E. Gubinelli, et al., “Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients,” Clinical and Developmental Immunology, vol. 2013, Article ID 410521, 5 pages, 2013. https://doi.org/10.1155/2013/410521.